Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company profile
Ticker
CLDX
Exchange
Website
CEO
Anthony Marucci
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Celldex Therapeutics Switzerland GmbH ...
IRS number
133191702
CLDX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
8-K
Other Events
21 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
28 Feb 23
8-K
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
21 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
9 Nov 22
Latest ownership filings
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
10 May 23
4
Rita Jain
21 Feb 23
3
Rita Jain
21 Feb 23
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
STATE STREET CORP
1 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.12 mm | 54.12 mm | 54.12 mm | 54.12 mm | 54.12 mm | 54.12 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.82 mm | 10.37 mm | 9.52 mm | 8.98 mm |
Cash used (since last report) | n/a | n/a | 23.59 mm | 22.60 mm | 20.76 mm | 19.57 mm |
Cash remaining | n/a | n/a | 30.53 mm | 31.52 mm | 33.37 mm | 34.55 mm |
Runway (months of cash) | n/a | n/a | 2.8 | 3.0 | 3.5 | 3.8 |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 166 |
Opened positions | 30 |
Closed positions | 19 |
Increased positions | 50 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 2.14 tn |
Total shares | 48.66 mm |
Total puts | 225.20 k |
Total calls | 531.60 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.06 mm | $314.89 bn |
Wellington Management | 4.65 mm | $207.16 bn |
BLK Blackrock | 3.22 mm | $143.73 bn |
RTW Investments | 3.08 mm | $137.46 bn |
Vanguard | 2.51 mm | $112.03 bn |
STT State Street | 2.29 mm | $102.13 bn |
Ra Capital Management | 2.08 mm | $92.48 bn |
Redmile | 1.98 mm | $88.13 bn |
BLVGF Bellevue | 1.80 mm | $80.23 bn |
Kynam Capital Management | 1.61 mm | $71.55 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 23 | Jain Rita | NQSO Common Stock | Grant | Acquire A | No | No | 42.34 | 17,100 | 724.01 k | 17,100 |
7 Dec 22 | Keler Tibor | Common Stock, par value $0.001 per share | Sell | Dispose S | No | No | 36.9283 | 16,860 | 622.61 k | 7,357 |
7 Dec 22 | Keler Tibor | Common Stock, par value $0.001 per share | Option exercise | Acquire M | No | No | 2.78 | 16,860 | 46.87 k | 24,217 |
7 Dec 22 | Keler Tibor | Incentive Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.78 | 16,860 | 46.87 k | 43,140 |
18 Aug 22 | Cavanaugh Sarah | Common Stock | Sell | Dispose S | No | No | 36.3757 | 1,355 | 49.29 k | 1,284 |
18 Aug 22 | Cavanaugh Sarah | Common Stock | Option exercise | Acquire M | No | No | 9.0165 | 1,355 | 12.22 k | 2,639 |
18 Aug 22 | Cavanaugh Sarah | Incentive Stock Option Common Stock | Option exercise | Dispose M | No | No | 9.0165 | 1,355 | 12.22 k | 10,103 |
17 Aug 22 | Young Diane C. | Common Stock | Option exercise | Acquire M | No | No | 2.71 | 45,000 | 121.95 k | 47,115 |
17 Aug 22 | Young Diane C. | Common Stock | Sell | Dispose S | No | No | 37.3008 | 19,000 | 708.72 k | 2,115 |
17 Aug 22 | Young Diane C. | Common Stock | Option exercise | Acquire M | No | No | 10.38 | 19,000 | 197.22 k | 21,115 |
News
4 Analysts Have This to Say About Celldex Therapeutics
31 May 23
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $73 Price Target
31 May 23
Celldex Therapeutics Presents Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023
15 May 23
10 Health Care Stocks With Whale Alerts In Today's Session
9 May 23
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $54
5 May 23
Press releases
Celldex Therapeutics to Present at Jefferies Healthcare Conference
2 Jun 23
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
31 May 23
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
15 May 23
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23